ANZCTR search results

Adequate physical activity and a healthy diet are important in reducing the risk of having a stroke. Stroke recurrence is common and medical management alone is not sufficient to manage the risk of stroke recurrence. This study aims to test the safety and feasibility of a diet and/or exercise program for stroke survivors aimed at reducing their risk of having another stroke. The programs run for 6 months duration. Both the diet and the exercise programs will be delivered via telehealth using teleconferencing technology, and this should make the program accessible to people who have had a stroke or transient ischaemic attack (TIA) all over Australia. We will be assessing how feasible the programs are by measuring the rate we can recruit people to the study, participants’ adherence to the programs and the completion rate by participants. We will also be asking participants about their experience to identify if improvements can be made. We will also be measuring each participants’ risk of having another stroke by measuring the amount of physical activity they do, their diet, and their blood pressure. If successful this study will be used to support further research in the area.

Historically, the management of knee OA has been variable, and often limited to pharmaceutical management and total joint replacement. Recently, evidence-based recommendations for the management of knee OA have been developed by scientific societies and health organisations. Best-practice guidelines for the treatment of knee OA focus on conservative (non-operative) multidisciplinary management that encompasses education, exercise, lifestyle modification and weight-loss where relevant, while promoting self-management. This body of evidence demonstrates that multidisciplinary conservative management of knee OA is efficacious. This observational study aims to discover how knee osteoarthritis patients are currently been managed by community physiotherapists, and if this aligns with recommended guidelines.

Oxidative stress occurs within a cell when there is an imbalance between highly reactive molecules and neutralising antioxidants. Oxidative stress can cause damage to healthy cells that lead to the development of numerous conditions including cancer, type 2 diabetes, neurodegenerative and cardiovascular disease, and contributes to the age-associated loss in tissue and organ function. On the other hand, oxidative stress plays a beneficial role in maintaining and improving cell function and overall human health. Research has yet to elucidate the mechanisms behind how the same reactive molecules can lead to completely opposing health outcomes. We will explore how oxidative stress, antioxidant treatment, and cell signalling can lead to opposing health outcomes by transiently eliciting both favourable and unfavourable oxidative stress and antioxidant treatment conditions in humans.

This study is aiming to investigate participants thoughts and feedback on new virtual reality technologies to assist with skin cancer eduation. Who is it for? You may be eligible for this study if you are aged 18 years or over and can attend the Queensland University of Technology for a once-off focus group. Study details All participants will complete a 45 minute audio-recorded focus group at the Queensland University of Technology. Discussion includes the concept of sun safety and new virtual reality technologies to assist with skin cancer prevention. This research will be used to influence future design and implementation of products that educate about skin cancer prevention.

The purpose of this study is to investigate how safe and tolerable BTX 1702 (either as a solution or a gel) is compared to a placebo (either a solution or a gel) when it is applied two times a day for a planned period of 42 days on the face of participants with papulopustular rosacea. The study will also look at whether BTX 1702 (either solution or gel) improves or worsens papulopustular rosacea compared to a placebo (gel or solution) and whether there are differences in the effectiveness of the BTX 1702 solution compared to the BTX 1702 gel. Participants will be monitored for any reactions or signs of irritation that may be caused by BTX 1702.

The primary purpose of this study is to analyse and report on outcomes following treatment for patients presenting to a single orthopaedic surgeon, Mr Timothy Lording, for management of conditions affecting the knee. This clinical registry will collate and store patient outcomes collected routinely as part of the standard clinical pathway for knee treatments. Outcomes will include objective joint function, patient reported outcomes (pain, satisfaction, quality of life), radiological findings and rates of revision surgery or complications. The main hypothesis arising from the registry is that specific factors present before treatment will predict the likelihood of a patient experiencing a positive, or negative outcome (whether clinically indicated or patient-reported) following surgery.

Cisplatin is a medication anti-cancer chemotherapy that can cause damage to the inner ear of patients leading to hearing loss. A medication called DB-020 has been developed as a potential treatment for this hearing loss. The purpose of this study is to test how the body tolerates and processes DB-020 injected into the inner ear and make sure it is safe. Who is it for? You may be eligible for this study if you are aged at least 18 years old and are undergoing chemotherapy for cancer with a medication called cisplatin. Study details This study has two parts. In the first part, all participants will have ear injections. One of the ears will be treated with DB-020 and the other will be treated with a salt-based solution (a placebo). The concentration of DB-020 used and the ear that receives DB-020 will be determined by chance (like flipping a coin). Treatment involves an ear injection in line with cisplatin chemotherapy - every 3 or 4 weeks. In the second part, all participants will have ear injections of DB-020 at a concentration determined by the first part. Depending on the safety analysis from the data in Part A, participants will receive one ear with placebo and the other with DB-020, or DB-020 in both ears. As part of this study, all participants will provide blood samples; answer questionnaires and have hearing tests. It is hoped this research will provide some evidence that DB-020 can be used as a preventative treatment of hearing loss for patients receiving cisplatin treatment and provide the basis for further trials with this medication.

The research project is testing a potential new treatment for Idiopathic pulmonary fibrosis (IPF), called FTP-198. Before a new medicine can be approved for use in humans, it is necessary to confirm that it is safe and effective. Although laboratory and animal studies have been completed, this is the first time FTP-198 is being tested in humans. Therefore, side effects in human are unknown. Thus, the purpose of this study is to evaluate the safety and tolerability of single and multiple doses of FTP-198. The pharmacokinetics (PK) of FTP-198 in humans will also be determined. PK testing involves taking blood samples to measure how much of the drug gets into the blood stream, and how long the body takes to remove it or excrete it. When testing for PK, your sample will also be tested to determine the amount of LPA in your blood. This is called a pharmacodynamic (PD) parameter.

In our pilot observation, we found women who suffered from menstrual migraine to have poorer blood vessel function in the brain than women who did not suffer from migraine. Therefore, we hypothesise that improving and/or maintaining proper brain blood vessel function may potentially prevent the migraine from occurring. We believe that supplementing with resveratrol (a natural ingredient found in grapes and berries that is known to improve our cardiovascular and brain health) throughout the menstrual cycle may improve blood vessel function and ultimately prevent the menstrual migraine and improve the quality of life in sufferers. In this randomised, double-blind, placebo-controlled crossover trial, we will enrol 145 women aged between 18 and 50 who suffer from migraine +/- 3 days from their period for at least three out of their previous six menstrual cycles. Participants will take one 75mg resveratrol or one matching placebo capsule twice daily for three menstrual cycles before crossing over to the other treatment arm for another three menstrual cycles.

The aim of this study is to assess the safety and performance of a new vaccine delivery device that uses a patch to deliver vaccines. This study will show how the device performs, whether patients could use it themselves to apply the patches, and how long the patch should be left on the skin. No vaccine is used in this study. A placebo coating on the patch is used to represent the vaccine.